Summary by Moomoo AI
On August 1, 2024, Moderna, Inc. reported its financial results for the second quarter ended June 30, 2024. The company announced a decrease in total revenue to $241 million compared to $344 million in the same period in 2023, primarily due to decreased sales of its COVID-19 vaccine. Net product sales were reported at $184 million, a 37% decrease from the previous year. Despite this, Moderna revised its expected net product sales for 2024 to $3.0 to $3.5 billion, driven by its respiratory franchise. The company also reported a GAAP net loss of $1.3 billion and a GAAP EPS of $(3.33). Notably, Moderna received U.S. FDA approval for its RSV vaccine, mRESVIA, and began shipping in July, with the EMA issuing a positive opinion in June. Additionally, Moderna announced positive Phase 3 data for...Show More
